NICE lifts cost limit on drugs to improve access to end of life treatmentsBMJ 2009; 338 doi: http://dx.doi.org/10.1136/bmj.b3 (Published 06 January 2009) Cite this as: BMJ 2009;338:b3
- Zosia Kmietowicz
The NHS drugs watchdog has loosened the terms of approval for expensive treatments that extend life in patients with a short life expectancy. Drugs that would normally be ruled out of use on the NHS because they did not represent a cost effective use of resources are now more likely to be made available.
The National Institute for Health and Clinical Excellence (NICE) has issued its appraisal committees with supplementary advice when considering whether to approve treatments licensed for terminal illness that affect small numbers of patients, normally fewer than …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial